Ibex presents AI accuracy in prostate, breast, and gastric cancer diagnosis

Ibex Medical Analytics has announced promising results from multiple clinical studies conducted in collaboration with prestigious healthcare institutions. These studies, to be presented at the USCAP Annual Meeting, demonstrate the effectiveness of Ibex's AI-powered cancer diagnostics solutions, Galen™, in enhancing diagnostic quality and efficiency. Notably, research conducted at Brigham and Women's Hospital and Champalimaud Foundation highlights Galen Breast's high accuracy in identifying microinvasive carcinoma of the breast, while studies at the University of Pittsburgh Medical Center (UPMC) underscore Galen Prostate's performance in primary prostate cancer diagnosis. Additionally, research from Ohio State University Wexner Medical Center validates Galen Breast's effectiveness in detecting various types of breast cancer and Galen Gastric's diagnostic capabilities for gastric cancer and related lesions.

The studies address the growing complexity of cancer diagnosis and the global shortage of pathologists by leveraging AI-powered workflows and decision-support tools offered by Ibex's Galen platform. These tools aim to improve diagnostic accuracy, consistency, and efficiency in pathology laboratories, offering significant potential for personalised cancer therapies. The findings reflect positive feedback from pathologists, indicating high satisfaction with Galen's performance across different tissue types. Ibex will showcase these outcomes at the USCAP Annual Meeting, highlighting its commitment to transforming cancer diagnostics through innovative AI solutions in pathology.

Click here to read the original news story.